1. [Giant cell tumor of bone with rapid malignant course].
- Author
-
Lachat MR, Weber M, Cserhati MD, Honegger HP, and von Hochstetter AR
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Needle, Bone Neoplasms pathology, Bone Neoplasms surgery, Bone Transplantation, Curettage, Disease Progression, Fatal Outcome, Giant Cell Tumor of Bone diagnosis, Giant Cell Tumor of Bone pathology, Giant Cell Tumor of Bone surgery, Humans, Lung pathology, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Reoperation, Salvage Therapy, Ankle Joint pathology, Ankle Joint surgery, Bone Neoplasms diagnosis, Giant Cell Tumor of Bone secondary, Lung Neoplasms secondary, Tibia pathology, Tibia surgery
- Abstract
The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented. Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later. Multiple metastases appeared 6 months after initial presentation. Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease. Good palliation was achieved, and the patient felt well with less shortness of breath on exertion and was ambulatory with walking aids. The malignant nature of the tumor was not detected in the initial pathologic examinations. Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component. Malignancy in a giant cell tumor is a much debated diagnostic dilemma when a frank sarcomatous component is lacking. Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues. Surgical treatment should be commensurate. Monotherapy with Adriamycin or gemcitabine can be considered in order to inhibit the disease progression.
- Published
- 2004
- Full Text
- View/download PDF